These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28342317)

  • 21. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy.
    Piszczek R; Krajewski W; Subiela JD; Del Giudice F; Nowak Ł; Chorbińska J; Moschini M; Masson-Lecomte A; Bebane S; Cimadamore A; Grobet-Jeandin E; Rouprêt M; D'Andrea D; Mastroianni R; Gutierrez Hidalgo B; Gomez Rivas J; Mori K; Soria F; Laukhtina E; Mari A; Albisinni S; Gallioli A; Mertens LS; Pichler R; Marcq G; Łaszkiewicz J; Hałoń A; Carrion DM; Akand M; Pradere B; Shariat SF; Palou J; Babjuk M; Burgos Revilla J; Małkiewicz B; Szydełko T;
    Minerva Urol Nephrol; 2023 Oct; 75(5):591-599. PubMed ID: 37728495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
    Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
    Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
    Tully KH; Moschini M; von Rundstedt FE; Aziz A; Kluth LA; Necchi A; Rink M; Hendricksen K; Sargos P; Vetterlein MW; Seiler R; Poyet C; Krajewski W; Fajkovic H; Shariat SF; Xylinas E; Roghmann F
    Urol Oncol; 2020 Nov; 38(11):851.e19-851.e25. PubMed ID: 32739227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.
    Erben P; Sikic D; Wirtz RM; Martini T; Weis CA; Breyer J; Otto W; Keck B; Hartmann A; Bolenz C;
    Virchows Arch; 2019 Feb; 474(2):209-217. PubMed ID: 30483954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
    Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors of early second transurethral resection of non-muscle invasive bladder cancer 10 years of experience of a referral center.
    Žemličková B; Brisuda A
    Rozhl Chir; 2022; 101(3):119-128. PubMed ID: 35387468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
    Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.
    Sikic D; Wirtz RM; Wach S; Dyrskjøt L; Erben P; Bolenz C; Breyer J; Otto W; Hoadley KA; Lerner SP; Eckstein M; Hartmann A; Keck B
    Transl Oncol; 2019 Apr; 12(4):661-668. PubMed ID: 30831560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation.
    Sun JX; An Y; Xu MY; Liu CQ; Xu JZ; Xia QD; Wang SG
    Front Oncol; 2023; 13():1133161. PubMed ID: 37476386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
    Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
    Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.
    Eroglu A; Ekin RG; Koc G; Divrik RT
    Int J Clin Oncol; 2020 Apr; 25(4):698-704. PubMed ID: 31760524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting.
    Sharma AP; Singh PP; Chauhan R; Panda I; Devana SK; Bora GS; Mavuduru RS; Kakkar N; Kumar S; Mete U
    Indian J Urol; 2024; 40(2):127-132. PubMed ID: 38725894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA-Expression of
    Eckstein M; Wirtz RM; Gross-Weege M; Breyer J; Otto W; Stoehr R; Sikic D; Keck B; Eidt S; Burger M; Bolenz C; Nitschke K; Porubsky S; Hartmann A; Erben P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R
    J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149
    [No Abstract]   [Full Text] [Related]  

  • 38. Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study.
    Cheng X; Zhou X; Yi M; Xu S; Zhang C; Wang G
    BMC Urol; 2021 Sep; 21(1):136. PubMed ID: 34579695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
    BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.